Skip to main content
SpringerLink
Log in

Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma

  • Chapter
Thyroid Cancer

Abstract

The use of radioactive iodine (131I) in the ablation and treatment of well-differentiated thyroid carcinoma may be associated with side effects in numerous organ systems (Table 1). Although many articles address the side effects of radioiodine, the characterizations of these effects vary widely because of a host of different factors (Table 2). This chapter attempts to consolidate the literature by presenting, where appropriate, (1) the spectrum of signs and symptoms, as well as the frequency and severity of side effects, (2) a review of selected articles, (3) a discussion of preventive measures to lessen the frequency and severity of side effects, and/or (4) a discussion of the medical management when the side effect occurs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 339.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87:171–182.

    PubMed  CAS  Google Scholar 

  2. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39:1551–1554.

    PubMed  CAS  Google Scholar 

  3. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82:3637–3642.

    Article  PubMed  CAS  Google Scholar 

  4. Holmquest DL, Lake P. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-I31. J Nucl Med 1976; 17:307–309.

    PubMed  CAS  Google Scholar 

  5. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986; 27:637–640.

    PubMed  CAS  Google Scholar 

  6. Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In Freeman LM, Weissman HS, editors. Nuclear Medicine Annual 1983. New York: Raven Press, 1983:329–384.

    Google Scholar 

  7. Grayson RR. Factors which influence the radioactive iodine thyroidal uptake test. Am J Med 1960; 24:397–415.

    Article  Google Scholar 

  8. Bedikian AY, Valdivieso M, Heilbrun LK, et al. Glycerol: a successful alternative to dexamethasone for patients receiving brain irradiation for metastatic disease. Cancer Treat Rep 1978; 62:1081–1083.

    PubMed  CAS  Google Scholar 

  9. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14:1063–1075.

    PubMed  CAS  Google Scholar 

  10. Zettinig G, Hanselmayer G, Fueger B, et al. Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med 2002; 29:1428–1432.

    Article  CAS  Google Scholar 

  11. Bakheet SMB, Hammami MM, Hemidan A, et al. Radioiodine secretion in tears. J Nucl Med 1998; 39:1452–1454.

    PubMed  CAS  Google Scholar 

  12. Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42:738–743.

    PubMed  CAS  Google Scholar 

  13. Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002; 87:5817–5820.

    Article  PubMed  CAS  Google Scholar 

  14. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I-131 therapy. Ophthal Plast Reconstr Surg 2004; 20:126–129.

    Article  PubMed  CAS  Google Scholar 

  15. Schiff L, Stevens CD, Molle WE, et al. Gastric (and salivary) excretion of radioiodine in man (preliminary report). J Natl Cancer Inst 1947; 7:349–354.

    CAS  PubMed  Google Scholar 

  16. Rice DH. Advances in diagnosis and management of salivary gland diseases. West J Med 1984; 140:238–249.

    PubMed  CAS  Google Scholar 

  17. Myant NB. Iodine metabolism of salivary glands. Ann NY Acad Sci 1960; 85:208.

    Article  PubMed  CAS  Google Scholar 

  18. Freinkel N, Ingbar SH. Concentration gradients for inorganic I-131 and chloride in mixed human saliva. J Clin Invest 1953; 32:1077–1084.

    Article  PubMed  CAS  Google Scholar 

  19. Honour AJ, Myant NB, Rowlands EN. Secretion of radioiodine in digestive juices and milk in man. Clin Sc 1952; 11:449–462.

    CAS  Google Scholar 

  20. Jhiang SM, Cho JY, Ryu KY, et al. An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139:4416–4419.

    Article  PubMed  CAS  Google Scholar 

  21. Rice DH. Advances in diagnosis and management of salivary gland diseases. West J Med 1984; 140:238–249.

    PubMed  CAS  Google Scholar 

  22. Batsakis JG. Physiology. In Cummings CW, Schuller DE, editors. Otolaryngology-Head and Neck surgery, vol. 2. St. Louis, MO: Mosby-Year Book, 1998; 1210–1222.

    Google Scholar 

  23. Van Nostrand DV, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J Nucl Med 1986; 27:1519–1527.

    PubMed  Google Scholar 

  24. Kahn S, Waxman A, Ramanna L, et al. Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC). J Nucl Med 1994; 35:15P.

    Google Scholar 

  25. Burmeister LA, du Cret RP, Mariash CN. Local reaction to radioiodine in the treatment of thyroid cancer. Am J Med 1991; 90:217–222.

    PubMed  CAS  Google Scholar 

  26. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986; 59:45–51.

    PubMed  CAS  Google Scholar 

  27. Albrecht HH, Creutzig H. Salivary gland scintigraphy after radioiodine therapy. Functional scintigraphy of the salivary gland after high dose radioiodine therapy. Fortschr Rontgenstr 1976; 125:546–551.

    Article  CAS  Google Scholar 

  28. Tubiana M, Lacour J, Monnier JP, et al. External radiotherapy and radioiodine in the treatment of 359 thyroid cancers. Br J Radiol 1975; 48:894–907.

    PubMed  CAS  Google Scholar 

  29. Allweiss P, Braunstein GD, Katz A, Waxman A. Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med 1984; 25:755–758.

    PubMed  CAS  Google Scholar 

  30. Pan MS. Follow-up study of side effects for iodine-131 treatment in patients with differentiated thyroid cancer. J Nucl Med 2004; 5S:386P.

    Google Scholar 

  31. Maheshwari YK, Strattton Hill C, Haynie TP, et al. Iodine-131 therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 1981; 47:664–671.

    Article  PubMed  CAS  Google Scholar 

  32. Tollefsen HR, De Cosse JJ, Hutter RVP. Papillary carcinoma of the thyroid. A clinical and pathological study of 70 fatal cases. Cancer 1964; 17:1035–1043.

    Article  PubMed  CAS  Google Scholar 

  33. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996; 21:780–782.

    Article  PubMed  CAS  Google Scholar 

  34. Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden hospital experience. Br J Radiol 1984; 57:323–327.

    PubMed  CAS  Google Scholar 

  35. Schneyer LH, Tanchester D. Some oral aspects of radioactive iodine therapy for thyroid disease. NYJ Dent 1954; 24:308–309.

    Google Scholar 

  36. Mandel S, Mandel L. Persistent sialadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg 1999; 57:738–741.

    Article  PubMed  CAS  Google Scholar 

  37. Malpani BL, Samuel AM, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 1996; 35:535–540.

    Article  PubMed  CAS  Google Scholar 

  38. Spiegel W, Reiners C, Borner W. Sialadenitis following iodine-131 therapy for thyroid carcinoma. J Nucl Med 1985; 26:816.

    Google Scholar 

  39. Reiners C, Eichner R, Eilles C, et al. Kamera-funktionsszintigraphie der kopfspeicheldrusen nach hoch-dosierter radiojodtherapie bei schilddrusenkarzinoma patienten. In Nuklearmedizin, Schmidt HAE, Riccabona G, editors. Stuttgart, New York: Schattauer 1980; 477–481.

    Google Scholar 

  40. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13:265–271.

    Article  PubMed  CAS  Google Scholar 

  41. Laupa MS, Toth BB, Keene HJ. Effect of radioactive iodine therapy on salivary flow rates and oral streptococcus mutants prevalence in patients with thyroid cancer. Oral Surg Oral Med Oral Pathol 1993; 75:312–317.

    Article  PubMed  CAS  Google Scholar 

  42. Busnell DL, Boles MA, Kaufman GE, et al. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med 1992; 33:2214–2221.

    Google Scholar 

  43. Davies AN. The management of xerostomia: a review. Eur J Cancer Care 1997; 6:209–214.

    Article  CAS  Google Scholar 

  44. Nakada K, Hirata K, Ishibashi T, et al. Cevimeline hydrochloride hydate in treating salivary gland dysfunction following radioiodine therapy for thyroid cancer. J Nucl Med 2004; 45S:17P.

    Google Scholar 

  45. Ericson T, Lindberg A. Clinical trial of a saliva stimulating tablet SST. Tandjakartidningen 1982; 74:713–716.

    CAS  Google Scholar 

  46. Blom M, Lunderberg T. Long term follow up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Diseases 2000; 6:15–24.

    Article  PubMed  CAS  Google Scholar 

  47. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology 1986; 5:75–99.

    Article  PubMed  CAS  Google Scholar 

  48. Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly; the SEE project. J Rheumatol 1998; 25:486–491.

    PubMed  CAS  Google Scholar 

  49. Donachi I. Biologic effects of radiation on the thyroid. In Werner SC, Ingbar SH, editors. The Thyroid New York: Harper & Row, 1978; 274–283.

    Google Scholar 

  50. Goolden AWG, Mallard JR, Farran HEA. Radiation sialitis following radioiodine therapy. Br J Radiol 1957; 30:210–212.

    Article  PubMed  CAS  Google Scholar 

  51. Kulkarni K, Kim SM, Intenzo C. Can salivary gland uptakes on a diagnostic I-131 scan predict acute salivary gland dysfunction in patients receiving radioiodine therapy for thyroid cancer? J Nucl Med 2004; 5S:291P.

    Google Scholar 

  52. Shaw LM, Bonner HS, Schuchter L, et al. Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol 1999; 26:34–36.

    PubMed  CAS  Google Scholar 

  53. Werner-Wasik M. Future development of amifostine as a radioprotectant. Semin Oncol 1999; 26:129–1234.

    PubMed  CAS  Google Scholar 

  54. Dorr RT, Holmes BC. Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 1999; 26:108–119.

    PubMed  CAS  Google Scholar 

  55. Hall P, Holm LE, Lundell G, Ruden BI. Tumors after radiotherapy for thyroid cancer. Acta Oncol 1992; 31:403–407.

    PubMed  CAS  Google Scholar 

  56. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-amiopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double blind multi-arm trial. Cancer Biother Radiopharm 1999; 13:337–347.

    Google Scholar 

  57. Levy HA, Park CH. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med 1987; 12:303–307.

    Article  PubMed  CAS  Google Scholar 

  58. Freitas JE, Gross MD, Ripley S, Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer; current status report. Semin Nucl Med 1985; 15:106–131.

    Article  PubMed  CAS  Google Scholar 

  59. Nakada K, Ishibashi T, Takei K, et al. Does lemon candy decrease salivary gland damage following radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46:261–266.

    PubMed  Google Scholar 

  60. Varma VM, Dai WL, Henkin RI. Taste dysfunction in patients with thyroid cancer following treat with I-131. J Nucl Med 1992; 33:996.

    Google Scholar 

  61. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol 1987; 103:318–324.

    PubMed  CAS  Google Scholar 

  62. Norby EH, Neutze JH, Van Nostrand D, et al. Nasal radioactive iodine uptake: a prospective study of frequency, intensity and pattern. J Nucl Med 1990; 31:52–54.

    PubMed  CAS  Google Scholar 

  63. Levenson D, Coulec S, Sonnenberg M, et al. Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Ann Intern Med 1994; 120:576–578.

    PubMed  CAS  Google Scholar 

  64. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States in 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 2000; 89:202–217.

    Article  PubMed  CAS  Google Scholar 

  65. Goolden AWG, Kam KC, Fitzpatrick ML, Munro AJ. Oedema of the neck after ablation of the thyroid with radioactive iodine. Br J Radiol 1986; 59:583–586.

    PubMed  CAS  Google Scholar 

  66. Cooper DS, Ridgway EC, Maloof F. Unusual types of hyperthyroidism. Clin Endocrinol Metab 1978; 7:199–220.

    PubMed  CAS  Google Scholar 

  67. Smith R, Blum C, Benua RS, Fawwaz R. Radioactive iodine treatment of metastatic thyroid carcinoma with clinical thyrotoxicosis. Clin Nucl Med 1985; 10:874–875.

    Article  PubMed  CAS  Google Scholar 

  68. Ikejiri K, Furuyama M, Muranaka T, et al. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nucl Med 1997; 22:227–230.

    Article  PubMed  CAS  Google Scholar 

  69. Trunnell JB, Marinelli LD, Duffy BJ Jr., et al. The treatment of metastatic thyroid cancer with radioactive iodine: credits and debits. J Clin Endocrinol 1949; 9:1138–1152.

    CAS  Google Scholar 

  70. Cerletty JM, Listwan WJ. Hyperthyroidism due to functioning metastatic thyroid carcinoma. Precipitation of thyroid storm with therapeutic radioactive iodine. JAMA 1979; 242:269–270.

    Article  PubMed  CAS  Google Scholar 

  71. Winslow CP, Meyers AD. Hypocalcemia as a complication of radioiodine therapy. Am J Otolaryngol 1998; 19:401–403.

    Article  PubMed  CAS  Google Scholar 

  72. Glazebrook GA. Effect of decicurie prescribed activity of radioactive I-131 on parathyroid function. Am J Surg 1987; 154:368–373.

    Article  PubMed  CAS  Google Scholar 

  73. Lee TC, Harbert JC, Dejter SW, et al. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant. J Nucl Med 1985; 26:49–50.

    PubMed  CAS  Google Scholar 

  74. Pochin EE. Radioiodine treatment of thyroid cancer. In Hahn PF, editor. Therapeutic Use of Artificial Radioisotopes. New York: John Wiley & Sons, 1956; 195.

    Google Scholar 

  75. Fajardo L. G LF, Berthrong M, Anderson, editors. Radiation Pathology. Oxford: University Press, 2001.

    Google Scholar 

  76. Rall JE, Alpers JB, Lewallen CG, et al. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab 1957; 17:1263–1276.

    PubMed  CAS  Google Scholar 

  77. Aldrich LB, Sisson JC, Grum CM. Pulmonary function in thyroid carcinoma metastatic to the lung. J Endocrinol Invest 1987; 10:111–116.

    PubMed  CAS  Google Scholar 

  78. Menzel C, Grunwald F, Schomburg A, et al. ”High-dose“ radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996; 37:1496–1503.

    PubMed  CAS  Google Scholar 

  79. Bennett DE, Million RR, Ackerman IV. Bilateral radiation pneumonitis. A complication of the radiotherapy of bronchogenic carcinoma. Cancer 1969; 23:1001–1018.

    Article  PubMed  CAS  Google Scholar 

  80. Fulkerson WJ, McLendon RE, Prosnitz LR. Adult respiratory distress syndrome after limited radiotherapy. Cancer 1986; 57:1941–1946.

    Article  PubMed  CAS  Google Scholar 

  81. Monson JM, Stark P, Reily JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. Cancer 1998; 82:842–850.

    Article  PubMed  CAS  Google Scholar 

  82. Morgan GW, Pharm B, Breit SN. Radiation and the lung. Int J Radiat Oncol Biol Phys 1995; 31:361–369.

    Article  PubMed  CAS  Google Scholar 

  83. Choi NC, Kanarek DJ, Kazemi H. Physiologic changes in pulmonary function after thoracic radiotherapy for patients with lung cancer and role of regional pulmonary function studies predicting postradiotherapy pulmonary function before radiotherapy. Cancer Treat Symp 1985; 2:119–130.

    Google Scholar 

  84. Mah K, Van Dyk J, Keane T, Poon PY. Acute radiation-induced pulmonary damage: a clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:179–188.

    PubMed  CAS  Google Scholar 

  85. Smith JC. Radiation pneumonitis. A review. Am Rev Respir Dis 1963; 87:647–665.

    PubMed  CAS  Google Scholar 

  86. Carmel RJ, Kaplan HS. Mantle irradiation for Hodgkin’s disease. An analysis of technique, tumor eradication and complications. Cancer 1976; 37:2813–2825.

    Article  PubMed  CAS  Google Scholar 

  87. Fryer CJH, Fitzpatrick PJ, Rider WD, et al. Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 1978; 4:931–936.

    PubMed  CAS  Google Scholar 

  88. McDonald S, Rubin P, Philips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995; 31:1187–1203.

    Article  PubMed  CAS  Google Scholar 

  89. Fowler JF, Travis EL. The radiation pneumonitis syndrome in halfbody radiation therapy. Int J Radiat Oncol Biol Phys 1978; 4:1111–1113.

    PubMed  CAS  Google Scholar 

  90. Keane T, Van Dyk J, Rider WD. Idiopathic interstitial pneumonia following bone marrow transplantation. The relationship with total body irradiation. Int J Radiat Oncol Biol Phys 1981; 7:1365–1370.

    PubMed  CAS  Google Scholar 

  91. Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86:81–92.

    PubMed  CAS  Google Scholar 

  92. Leeper R. Controversies in the treatment of thyroid carcinoma: the New York Memorial Hospital approach. Thyroid Today 1982; 4:1–6.

    Google Scholar 

  93. Leeper RD. The effect of I-131 therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 1973; 36:1143–1152.

    PubMed  CAS  Google Scholar 

  94. Samuel AM, Unnikrishnan TP, Baghel NS, Rajashekharrao B. Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity. J Nucl Med 1995; 36:783–787.

    PubMed  CAS  Google Scholar 

  95. Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection of and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29:1790–1794.

    PubMed  CAS  Google Scholar 

  96. Hindiè E, Melliere D, Lange F, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? J Nucl Med 2003; 30;974–981.

    Article  CAS  Google Scholar 

  97. Nemec J, Zamrazil V, Pohunkova D, Roohling S. Radioiodide treatment of pulmonary metastases of differentiated thyroid cancer; results and prognostic factors. Nuklearmedizin 1979; 18:86–90.

    PubMed  CAS  Google Scholar 

  98. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982–992.

    Article  PubMed  CAS  Google Scholar 

  99. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60:376–380.

    Article  PubMed  CAS  Google Scholar 

  100. Leeper RD, Shimaoka K. Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 1980; 9:383–404.

    PubMed  CAS  Google Scholar 

  101. Quimby ES, Feitelberg S, Laughlin JS, et al. NCRP Report 37: Precautions in the management of patients who have received therapeutic amounts of radionuclides. Washington, DC: National Council on Radiation Protection, 1970.

    Google Scholar 

  102. US Nuclear Regulatory Commission 1997 Criteria for release of individuals administered radioactive materials. Federal Reg 1997; 62:4120.

    Google Scholar 

  103. Marcus CS, Siegel JA. NRC absorbed dose reconstruction for family members of I-131 therapy patient: case study and commentary. J Nucl Med 2004; 45:13N–16N.

    PubMed  Google Scholar 

  104. Kinuya S, Hwang E, Ikeda E, et al. Mallory-Weiss Syndrome caused by iodine-131 therapy for metastatic thyroid carcinoma. J Nucl Med 1997; 38:1831–1832.

    PubMed  CAS  Google Scholar 

  105. Balan KK, Raouf AH, Critchley M. Outcome of 249 patients attending a nuclear medicine department with well-differentiated thyroid cancer; a 23 year review. Br J Radiol 1994; 67:283–291.

    PubMed  CAS  Google Scholar 

  106. Dobyns BM, Maloof F. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol 1951; 11:1323–1360.

    CAS  Google Scholar 

  107. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk—adapted approach. J Nucl Med 2003; 44:451–456.

    PubMed  CAS  Google Scholar 

  108. Grunwald F, Schomburg A, Menzel C, et al. Blood count changes after radioiodine treatment in thyroid carcinoma. Med Klin 1994; 89:522–528.

    CAS  Google Scholar 

  109. Haynie T, Beierwaltes W. Hematologic changes observed following therapy for thyroid carcinoma. J Nucl Med 1963; 4:85–91.

    PubMed  CAS  Google Scholar 

  110. Keldsen N, Mortensen BT, Hansen HS. Bone marrow depression due to I-131 treat of thyroid cancer. Ugeskr Laeger 1988; 50:2817–2819.

    Google Scholar 

  111. Matthies A, Bender H, Distelmaier M, et al. Efficacy and side effects of high dose iodine-131 therapy in metastatic thyroid carcinoma. J Nucl Med 2004; 45S:189P.

    Google Scholar 

  112. Petrich T, Widjaja A, Musholt TJ, et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur J Nucl Med 2001; 28:203–208.

    Article  PubMed  CAS  Google Scholar 

  113. Robeson WR, Ellwood JE, Margulies P, Margouleff D. Outcome and toxicity associated with maximum safe dose radioiodine treatment of metastatic thyroid cancer. Clin Nucl Med 2002; 27:556–666.

    Article  PubMed  Google Scholar 

  114. Schober O, Gunter HH, Schwarzrock R, Hundeshagen H. Hamatologische langzeitveranderungen bei der Radiojodtherapie des Schilddrusenkarzinoms. Strahlenther Onkol 1987; 163;464–474.

    PubMed  CAS  Google Scholar 

  115. Schumichen C, Schmitt E, Scheuffele C. Influence of the therapy concept onto the prognosis of thyroid carcinoma. Nuklearmedizin 1983; 22:97–105.

    PubMed  CAS  Google Scholar 

  116. Kuhn JM, Rieu M, Wolf LM, et al. Hematologic repercussions of disorders of thyroid secretion. Presse Med 1984; 13:421–425.

    Article  PubMed  CAS  Google Scholar 

  117. Donate RM, Gallagher NI. Hematologic alteration associated with endocrine disease. Med Clin N Am 1968; 52;231–241.

    Google Scholar 

  118. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989; 69:186–190.

    PubMed  CAS  Google Scholar 

  119. Vini L, Hyer S, Al-Saadi A, et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002; 78:92–93.

    Article  PubMed  CAS  Google Scholar 

  120. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37:606–612.

    PubMed  CAS  Google Scholar 

  121. Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 1995; 36:21–27.

    PubMed  CAS  Google Scholar 

  122. Wichers M, Benz E, Palmedo H, et al. Testicular function after radiodiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000; 27:503–507.

    Article  PubMed  CAS  Google Scholar 

  123. Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in men following I (131). therapy for thyroid cancer. Clin Endocrinol 2002; 56:755–758.

    Article  CAS  Google Scholar 

  124. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35:1418–1422.

    PubMed  CAS  Google Scholar 

  125. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer. J Nucl Med 1976; 17:460–464.

    PubMed  CAS  Google Scholar 

  126. Maxon HR III, Smith HD. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clinics North Am 1990; 19:685–718.

    Google Scholar 

  127. Bitton R, Sachmechi I, Benegalrao Y, Schneider BS. Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 1993; 77:1423–1426.

    Article  PubMed  CAS  Google Scholar 

  128. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131administration from thyroid cancer. Br J Cancer 1997; 75:734–739.

    PubMed  Google Scholar 

  129. Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer 1991; 64:159–163.

    PubMed  CAS  Google Scholar 

  130. Pochin EE. Radioiodine therapy of thyroid cancer. Semin Nucl Med 1971; 1:503–515.

    Article  PubMed  CAS  Google Scholar 

  131. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638–1644.

    Article  PubMed  CAS  Google Scholar 

  132. Berthe E, Henry-Amar M, Michels JJ, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2004; 31:685–691.

    Article  PubMed  Google Scholar 

  133. Wiseman JC, Hales IB, Joasoo A. Two cases of lymphoma of the parotid gland following ablative radioiodine therapy for thyroid carcinoma. Clin Endocrinol 1982; 17:85–89.

    CAS  Google Scholar 

  134. Rodriguez-Cuevas S, Ocampo LB. A case report of mucoepidermoid carcinoma of the parotid gland developing after radioiodine therapy for thyroid carcinoma. Eur J Surg Oncol 1995; 21:692.

    Article  PubMed  CAS  Google Scholar 

  135. Spitzberg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998; 83:1746–1751.

    Article  Google Scholar 

  136. Hammami MM, Bakheet S. Radioiodine breast uptake in non-breast feeding women. Clinical and scintigraphic characteristics. J Nucl Med 1996; 37:26–31.

    PubMed  CAS  Google Scholar 

  137. Adjadj E, Rubino C, Shamsaldim A, et al. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003; 98:1309–1317.

    Article  PubMed  Google Scholar 

  138. Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977; 56:171–196.

    Article  PubMed  CAS  Google Scholar 

  139. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. World J Surg 1994; 18:600–604.

    Article  PubMed  CAS  Google Scholar 

  140. Tuttle RM, Pentlow K, Qualey R, et al. Empiric radioactive iodine (RAI) dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with metastatic thyroid cancer. (abstract #177). 74th Annual meeting, American Thyroid Association, Los Angeles CA, October 10–13, 2002, p 198.

    Google Scholar 

  141. Atkins FB, Van Nostrand D, Kulkarni K, et al. The frequency with which empiric amounts of radioiodine “over-” or “under-” treat patients with metastatic well-differentiated thyroid cancer. J Nucl Med 2005; 46:129P.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, Washington Hospital Center, Washington, DC

    Douglas Van Nostrand MD, FACP, FACNP (Director)

  2. Nuclear Medicine Services, Department of Radiology, St. Joseph Mercy Hospital, Ann Arbor, MI

    John Freitas MD (Director, Clinical Professor of Radiology)

  3. University of Michigan Medical School, Ann Arbor, MI

    John Freitas MD (Director, Clinical Professor of Radiology)

Authors
  1. Douglas Van Nostrand MD, FACP, FACNP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Freitas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD, MPH, MACP  & Douglas Van Nostrand MD, FACP, FACNP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Van Nostrand, D., Freitas, J. (2006). Side Effects of 131I for Ablation and Treatment of Well-Differentiated Thyroid Carcinoma. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_52

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-995-0_52

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-462-3

  • Online ISBN: 978-1-59259-995-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation